Pt-141

Overview

PT-141 (bremelanotide, marketed as Vyleesi) is an FDA-approved peptide for hypoactive sexual desire disorder in premenopausal women. Rather than acting on blood flow, it works through melanocortin receptors in the brain to increase sexual desire, which makes it genuinely different from PDE5 inhibitors. The clinical case is strongest in women; human data in men is limited. As a peptide it requires reconstitution and subcutaneous injection, with purity and storage mattering.

This page was reviewed by Dr. Dimitar Marinov, MD, PhD, a nutrition researcher. In his assessment, PT-141 is highly effective at enhancing sexual desire without affecting hormones or fertility, and the main contraindication is uncontrolled hypertension, since the peptide can transiently raise blood pressure in some people.

The Bottom Line

PT-141 is one of the few peptides here with FDA approval and a real human-trial record behind it, so the core claim, that it boosts desire, is well supported. The caveats are practical: the strong evidence is in women, off-label use in men leans on weaker data, nausea is genuinely common, and the literature carries a couple of integrity flags worth noting.

Evidence Quality

The A+ grade is weighted across 65 peer-reviewed studies including 18 RCTs and 3 meta-analyses, with 39 supporting findings against 4 refuting. The dataset also carries flags: 1 retracted and 1 criticised study, a reminder to read individual claims carefully.

What the Research Shows

An observational study found bremelanotide reduced body weight and caloric intake in obese women. A long-term observational study reported it improved sexual desire in premenopausal women with HSDD over 52 weeks. An RCT showed it significantly increased sexual desire and reduced distress in women with sexual dysfunction, with a favorable safety profile. Together these support the desire-enhancing effect while underscoring that the robust evidence sits in women.

Community Sentiment

Across 129 reports, sentiment ran 51% positive, 15% neutral, and 34% negative, with mentions rising steeply. The most-cited effects were increased libido, better arousal, and erections. The most-cited side effects were nausea (by far the most common), priapism, and insomnia, an important counterweight to the upside.

Dosage

The standard dose is 1.75 mg subcutaneously as needed, taken about 45 minutes before sexual activity. Per the Vyleesi prescribing information, no more than one dose should be used in 24 hours and no more than eight doses per month.

Effectiveness and Availability

PT-141 is clinically validated, works through a different mechanism than PDE5 inhibitors (so it may help when those fail), and enhances psychological 'wanting' rather than vasodilation. It is available by prescription as Vyleesi, with the branded version being expensive, and is also sold by peptide suppliers as a research chemical.